US Edition
Your source for latest news
LifestyleConsumer Safety

Bone-Health Supplement Recalled Nationwide Over Undeclared Milk Allergen

bioQuad Life Sciences says two lots of its OsteoDenx joint and bone supplement contained milk-derived lactoferrin that was never listed on the carton, a labeling lapse the FDA warns could trigger a serious reaction in anyone with a milk allergy.

PN
By PressTemps NewsroomPublished November 14, 2026 · 5 min read
Bone-Health Supplement Recalled Nationwide Over Undeclared Milk Allergen
Illustrative photo of dietary supplement capsules (fish oil pictured); not a photo of the actual recalled OsteoDenx product. Photo: Oddman47 / Wikimedia Commons, CC0 1.0 Universal Public Domain Dedication
What to know
bioQuad Life Sciences recalled two lots of its OsteoDenx bone and joint capsules, in both 30- and 60-count bottles, after finding they contained undeclared cow's-milk-derived lactoferrin.
Affected lots are 0524100 (expires May 2027) and 0625041 (expires August 2028), sold nationwide from November 1, 2024 through November 11, 2026 via bioquad.com, Amazon, resellers and a Redwood City, California dental clinic.
The company says no illnesses have been reported and the problem was found during a routine inspection, not after a consumer complaint.
Affected buyers can get a full refund or a replacement in corrected packaging by calling bioQuad at (714) 660-1031 or emailing [email protected].

A dietary supplement marketed to older adults for bone and joint health has been recalled nationwide after its manufacturer discovered that two lots of the product contained cow's milk that was never listed on the label, creating what federal regulators warn is a risk of a serious or life-threatening reaction for anyone with a milk allergy.

bioQuad Life Sciences, based in Yorba Linda, California, said the undeclared ingredient was traced to lactoferrin, a milk-derived protein that serves as the core active compound in its OsteoDenx capsules. The company's notice was posted on November 13 through the Food and Drug Administration's recalls database, which publishes company-issued alerts as a public service. The alert was also carried the same day through a wire distribution notice confirming the company's account of the problem.

What was recalled

The recall covers four specific items: 30-capsule and 60-capsule bottles of OsteoDenx, each affected in two lot numbers. The 30-capsule bottles, UPC 8 57294 00722 8, are recalled under lot 0524100 (expiring May 2027) and lot 0625041 (expiring August 2028). The 60-capsule bottles, UPC 8 57294 00734 1, carry the same two lot numbers and expiration dates. Both the lot number and expiration date are printed on the side panel of the carton, not on the bottle itself, which the company's notice says is the easiest way for a buyer to check whether a bottle in a medicine cabinet is affected.

According to the recall notice, the capsules were sold nationwide between November 1, 2024, and November 11, 2026, through the company's own website, through Amazon.com, through independent resellers, and at a dental clinic in Redwood City, California. bioQuad said the problem surfaced during a routine inspection rather than after any report of a reaction, and that it has received no reports of illness connected to the product. The company has stopped distribution until it can produce new cartons with a corrected allergen statement.

A health-and-wellness label running on an old ingredient

OsteoDenx is one of several products sold by bioQuad, a direct-sales wellness company that also recruits customers as "ambassadors" who resell its line. Its own marketing describes the capsules as a "patented, clinically-proven, dual-action supplement" intended to support bone density and joint cartilage in older adults, built around a proprietary compound the company calls R-ELF, a ribonuclease-enriched form of lactoferrin. The company's current product listing for OsteoDenx already discloses that the formula contains milk and fish allergens, which suggests the recall centers on a packaging or labeling failure on the affected cartons rather than a change in the supplement's underlying formula.

Undeclared allergens are one of the most common reasons the FDA posts a food or supplement recall, alongside bacterial contamination. Milk is one of nine ingredients that food and supplement labels are legally required to disclose under federal allergen-labeling rules the FDA enforces, a list that also includes egg, peanuts, tree nuts, soy, wheat, fish, shellfish and, since 2023, sesame. The nonprofit advocacy group Food Allergy Research and Education estimates that roughly 33 million Americans live with at least one food allergy, and milk remains among the most common triggers in both children and adults. For most people, a dairy-derived ingredient in a joint supplement would be an afterthought; for someone with a true milk allergy, as opposed to simple lactose intolerance, exposure can trigger hives, difficulty breathing or anaphylaxis.

Who is affected and what buyers should do

The recall reaches anyone who bought OsteoDenx in the two recalled lots over the past two years, a pool that includes bioQuad's direct customers, Amazon shoppers, buyers through outside resellers, and patients of the Redwood City dental practice that carried the product. The company is advising consumers who are allergic or sensitive to milk not to take the capsules and says they may simply discard them. Anyone who bought an affected lot can request a full refund or a replacement in corrected packaging.

bioQuad has set up a dedicated line for questions, (714) 660-1031, staffed weekdays from 9:30 a.m. to 5 p.m. Pacific time, and an email address, [email protected], which the company says it checks the next business day for messages sent after hours or on weekends. The notice lists Sreus Naidu as the media contact for the recall. The FDA's own recalls listing notes, as it does with every company-issued notice, that posting the alert is a public service and does not amount to an endorsement of the product or the company.

What happens next

Because no illnesses have been reported, the FDA has not yet assigned the recall a risk classification, a designation the agency typically adds in a later weekly enforcement report once its own review is complete. That classification determines how the recall is treated in the agency's permanent records and can take several weeks to appear. In the meantime, the practical burden falls on consumers: checking any bottle of OsteoDenx against the two recalled lot numbers, and anyone with a milk allergy setting the product aside regardless of which lot they have, since the company's advisory applies broadly to allergic or sensitive consumers rather than only to the specific cartons named. bioQuad has not said how many bottles are affected or how it plans to prevent the same labeling gap on future runs, and its notice does not set a deadline for consumers to request refunds.

The episode is a reminder that supplement labels, unlike many packaged foods, are not independently verified by the FDA before they reach store shelves or an online checkout page. Manufacturers are legally responsible for accurately disclosing major allergens, and the agency generally learns of a lapse either through a company's own inspection and testing, as bioQuad describes here, or through a complaint. That gap is one reason allergy specialists generally advise checking a product's label at every purchase, even for a brand used safely before, since a formula or a single packaging run can change without any obvious signal to the buyer.

More on this story

All Lifestyle